Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive symbols : PLRX save search
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Published: 2024-02-04 (Crawled : 00:00) - globenewswire.com
PLRX | $12.505 -0.75% -0.76% 240K
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: -5.78%
liver positive fibrosis bexotegrast trial therapeutics
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: -1.24%
H: 0.0%
C: 0.0%
PLRX | $12.505 -0.75% -0.76% 240K
|
Health Technology
|
| O: 7.89%
H: 11.25%
C: 5.98%
liver positive fibrosis bexotegrast trial therapeutics
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures
Published: 2023-04-30 (Crawled : 20:20) - globenewswire.com
PLRX | $12.505 -0.75% -0.76% 240K
|
Health Technology
|
| O: -15.04%
H: 0.0%
C: -7.04%
positive bexotegrast trial therapeutics
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
Published: 2023-03-13 (Crawled : 12:20) - globenewswire.com
PLRX | $12.505 -0.75% -0.76% 240K
|
Health Technology
|
| O: -1.64%
H: 5.52%
C: 2.47%
pln-7480 trial therapeutics review positive sclerosing cholangitis
Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis
Published: 2023-01-22 (Crawled : 20:20) - globenewswire.com
PLRX | $12.505 -0.75% -0.76% 240K
|
Health Technology
|
| O: 55.66%
H: 4.17%
C: -13.58%
fibrosis trial therapeutics positive phase 2b
Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
Published: 2022-09-01 (Crawled : 14:20) - biospace.com/
PLRX | $12.505 -0.75% -0.76% 240K
|
Health Technology
|
| O: 1.76%
H: 4.84%
C: 3.47%
pln-7480 fibrosis trial therapeutics review positive phase 2b
Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis
Published: 2022-07-10 (Crawled : 00:00) - globenewswire.com
PLRX | $12.505 -0.75% -0.76% 240K
|
Health Technology
|
| O: 80.29%
H: 43.66%
C: 43.66%
pln-7480 fibrosis trial therapeutics positive phase 2b
Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-β Signaling in Healthy Volunteers
Published: 2022-02-28 (Crawled : 15:30) - biospace.com/
PLRX | $12.505 -0.75% -0.76% 240K
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
pln-7480 health phase 1b trial therapeutics phase 1 positive phase 2b
Pliant Therapeutics Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
Published: 2022-02-24 (Crawled : 23:00) - globenewswire.com
PLRX | $12.505 -0.75% -0.76% 240K
|
Health Technology
|
| O: 0.71%
H: 13.92%
C: 13.8%
pln-7480 phase 2 fibrosis trial therapeutics positive enroll phase 2b
Pliant Therapeutics Reports Positive Interim Results from Phase 2a PET Imaging Clinical Trial in Patients with Idiopathic Pulmonary Fibrosis
Published: 2021-09-07 (Crawled : 12:00) - biospace.com/
PLRX | $12.505 -0.75% -0.76% 240K
|
Health Technology
|
| O: 15.61%
H: 9.86%
C: -12.91%
phase 2 fibrosis positive results trial imaging phase 2b
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.